Zymeworks

September 10, 2019

Esmo 2019 preview – immunotherapies grab the rest of the late-breaker focus

Away from the main small-molecule focus of this year’s Esmo meeting, Keytruda flies the flag for immuno-oncology, including in a little-noticed mesothelioma study.

September 01, 2017

Macrogenics and J&J fallout could spell double trouble

July 05, 2017

Biotech floats come back with a vengeance

The biotech IPO market records its first billion dollar quarter in two years as demand for new issues recovers.

July 14, 2016

Biotech venture funding falls from 2015 peak

April 13, 2016

Zymeworks

Esmo 2019 preview – immunotherapies grab the rest of the late-breaker focus

Macrogenics and J&J fallout could spell double trouble

Biotech floats come back with a vengeance

Biotech venture funding falls from 2015 peak

First-quarter venture financing: the retrenchment begins

Latest Reports

Vantage Pharma, Biotech & Medtech Half-Year Review 2019

Vantage Pharma, Biotech and Medtech 2018 in Review

Editor's Picks

Car-T sales have disappointed, but has the sellside’s outlook shifted enough?

$1bn Corindus deal gets Healthineers off the acquisition blocks

Clovis investors feel more Lynparza pressure

A recap on the past few months of data digging and analysis

Oncology's haves and have-nots